National Institute For Pharmaceutical Technology & Education Inc.
Minneapolis, MN Doing business as Nipte
- UEI
- RKVKGV1CJDB8
- CAGE
- 4XQ36
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Tax Exempt)
- Other NAICS codes in SAM.gov
- SAM.gov registration date
- Physical address
- 717 Delaware St SE, Minneapolis, MN 55414, USA
- Website
- nipte.org
- Founded
- 2005
- Employees
- 1-10
- Estimated annual revenue
- $0-$1M
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Pharmaceuticals
- Profiles
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Contract obligations by fiscal year
| Fiscal year | Obligated |
|---|---|
| FY2027 To date | $0 |
| FY2026 | $2,151,882 |
| FY2025 | $0 |
| FY2024 | $0 |
| FY2023 | $1,544,048 |
Top agencies by obligations
| Rank | Agency | Obligated, FY2026–FY2027 | Share |
|---|---|---|---|
| 1 | Department of Health and Human Services | $2,151,882 |
Contract awards
Latest 5 listed here. See the rest on GovTribe.
Grant awards
Grant subawards
| Prime recipient | Prime award | Amount | Awarded |
|---|---|---|---|
| University Of Delaware | 70NANB21H085 | $222,600 |
Similar vendors
About the company
National Institute For Pharmaceutical Technology & Education Inc., doing business as Nipte, is a non-profit organization based in Minneapolis, Minnesota that conducts pharmaceutical manufacturing research and regulatory science development for the Food and Drug Administration, competing under full-and-open (no set-aside) BAA mechanisms as a prime recipient on definitive contracts and cooperative agreements.
Nipte's capability portfolio centers on advanced pharmaceutical manufacturing, drug quality control, and biosimilar characterization. The organization delivers research and development services in biotechnology and life sciences, with concrete work including a $5 million firm fixed price contract awarded September 2022 for model-based systems engineering applied to end-to-end liquid pharmaceutical manufacturing, a $3 million cost-plus-no-fee contract awarded September 2022 for continuous drug substance manufacturing from biomass-derived building blocks (extended through September 2027), a $1.52 million definitive contract awarded September 2026 under Executive Order 14398 for advanced pharmaceutical technology advancement, and a $634,642 definitive contract awarded September 2026 for an advanced CMC index and intelligence platform targeting drug quality control, shortage prediction, and strategic reshoring. Nipte also operates as a grant recipient under the National Science Foundation and the National Institute of Standards and Technology, including a cooperative agreement from the FDA's Center for Drug Evaluation and Research for developing a platform for biosimilar characterization and comparability in lyophilized and liquid formulations, and a project grant from the NSF Division of Engineering Education and Centers for a workshop on accelerating drug product development and regulatory evaluation.
Customer concentration is highly concentrated with the FDA. The top four funding agencies account for 88% of awards by count and 91% of combined potential value, with the FDA dominating at eleven awards and $12.8 million combined potential value. Activity is episodic — one award in 2013, one in 2019, four in 2022, one in 2023, and two in 2026 — with four awards (combined potential value $10.2 million) facing ultimate completion within the next twenty-four months and therefore representing recompete exposure. Nipte carries a single sub-award role: a grant sub-award from the University of Delaware for user requirement specification development on a vaccine formulation project, awarded February 2022. The vendor's $37.3 million in combined obligated dollars across all awards significantly exceeds the $14.1 million combined potential value, indicating mature projects with invoiced activity exceeding contract ceilings over the award portfolio's lifetime.
Quick answers
Is National Institute For Pharmaceutical Technology & Education Inc. registered in SAM.gov?
Yes. National Institute For Pharmaceutical Technology & Education Inc.'s SAM.gov registration is active through April 30, 2027.
How much has National Institute For Pharmaceutical Technology & Education Inc. received in federal contracts?
Federal contracts obligated $3,695,930 to National Institute For Pharmaceutical Technology & Education Inc. in fiscal years 2023 through 2027.
What is National Institute For Pharmaceutical Technology & Education Inc.'s most recent federal award?
National Institute For Pharmaceutical Technology & Education Inc.'s most recent federal contract award is BAA contract- FY26C2AP9 advanced CMC index and intelligence platform for drug quality control, shortage prediction, and… (75F40126C00069), from Food and Drug Administration, on September 30, 2026.
On GovTribe
See National Institute For Pharmaceutical Technology & Education Inc.'s full federal record
- Federal contract awards
- IDV awards
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors